Santos Joana Dos, Lopes Roberto I, Koyle Martin A
Division of Urology, The Hospital for Sick Children, Toronto, ON, Canada.
Can Urol Assoc J. 2017 Jan-Feb;11(1-2Suppl1):S64-S72. doi: 10.5489/cuaj.4411.
Bladder and bowel dysfunction (BBD) describes a spectrum of lower urinary symptoms (LUTS) accompanied by fecal elimination issues that manifest primarily by constipation and/or encopresis. This increasingly common entity is a potential cause of significant physical and psychosocial burden for children and families. BBD is commonly associated with vesicoureteral reflux (VUR) and recurrent urinary tract infections (UTIs), which at its extreme may lead to renal scarring and kidney failure. Additionally, BBD is frequently seen in children diagnosed with behavioural and neuropsychiatric disorders such as attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Patients with concomitant BBD and neuropsychiatric disorders have less favourable treatment outcomes. Early diagnosis and treatment of BBD are critical to avoid secondary comorbidities that can adversely impact children's kidney and bladder function, and psychosocial well-being. The majority of patients will improve with urotherapy, adequate fluid intake, and constipation treatment. Pharmacological treatment must only be considered if no improvement occurs after intensive adherence to at least six months of urotherapy ± biofeedback and constipation treatment. Anticholinergics remain the mainstay of medical treatment. Selective alpha-blockers appear to be effective for improving bladder emptying in children with non-neurogenic detrusor overactivity (DO), incontinence, recurrent UTIs, and increased post-void residual (PVR) urine volumes. Alpha-1 blockers can also be used in combination with anticholinergics when overactive bladder (OAB) coexists with functional bladder outlet obstruction. Minimally invasive treatment with onabotulinumtoxinA bladder injections, and recently neurostimulation, are promising alternatives for the management of BBD refractory to behavioural and pharmacological treatment. In this review, we discuss clinical presentation, diagnostic approach, and indications for behavioural, pharmacological, and surgical treatment of BBD in children based on a thorough literature review. Expert opinion will be used when scientific evidence is unavailable.
膀胱和肠道功能障碍(BBD)描述了一系列下尿路症状(LUTS),并伴有主要表现为便秘和/或大便失禁的排便问题。这种日益常见的病症是儿童及其家庭身体和心理社会负担的潜在原因。BBD通常与膀胱输尿管反流(VUR)和复发性尿路感染(UTI)相关,在极端情况下可能导致肾瘢痕形成和肾衰竭。此外,BBD在被诊断患有行为和神经精神疾病(如注意力缺陷多动障碍(ADHD)和自闭症谱系障碍(ASD))的儿童中也很常见。合并BBD和神经精神疾病的患者治疗效果较差。BBD的早期诊断和治疗对于避免可能对儿童肾脏和膀胱功能以及心理社会福祉产生不利影响的继发性合并症至关重要。大多数患者通过尿疗法、充足的液体摄入和便秘治疗会有所改善。只有在严格坚持至少六个月的尿疗法±生物反馈和便秘治疗后仍无改善时,才考虑药物治疗。抗胆碱能药物仍然是药物治疗的主要手段。选择性α受体阻滞剂似乎对改善非神经源性逼尿肌过度活动(DO)、尿失禁、复发性UTI以及排尿后残余(PVR)尿量增加的儿童的膀胱排空有效。当膀胱过度活动症(OAB)与功能性膀胱出口梗阻并存时,α-1受体阻滞剂也可与抗胆碱能药物联合使用。用A型肉毒杆菌毒素膀胱注射进行微创治疗,以及最近的神经刺激,是治疗对行为和药物治疗无效的BBD的有前景的替代方法。在本综述中,我们基于全面的文献综述,讨论儿童BBD的临床表现、诊断方法以及行为、药物和手术治疗的适应症。在缺乏科学证据时将采用专家意见。